Biotech's IPO rebound is picking up speed with larger offerings and stronger aftermarket performance.
The big picture: M&A, crossover rounds and improving public market performance are drawing capital back to the sector.
Biotech's IPO rebound is picking up speed with larger offerings and stronger aftermarket performance.
The big picture: M&A, crossover rounds and improving public market performance are drawing capital back to the sector.
